Treatment for Dupuytren's disease
Musculoskeletal fibroproliferative disorders, such as Dupuytren's disease may be treated by administering locally a TNF-α antagonist. TNF-α antagonists find particular utility in inhibiting the progression of early disease state Dupuytren's disease and other musculoskeletal fibroproliferative disorders and, in combination with extracellular matrix degradation agents (such as collagenase or matrix metalloproteinase I), treating advanced disease state Dupuytren's disease and, in particular inhibiting recurrence.
1. A method for treating a patient with early disease state periarticular fibrosis or adhesion comprising injecting an amount of a TNF-α antagonist effective to treat the patient directly at the site of the early disease state periarticular fibrosis or adhesion, so as to treat the patient.
2. A method of claim 1 , wherein the TNF-α antagonist is selected from one or more of Infliximab, Adalimumab, Certolizumab pegol, Golimumab or Etanercept.
3. A method of claim 1 , wherein the TNF-α antagonist is an anti-TNF-α antibody.
4. A method of claim 1 , wherein the TNF-α antagonist is Infliximab.
5. A method of claim 1 , wherein the TNF-α antagonist is Adalimumab.
6. A method of claim 1 , wherein the TNF-α antagonist is Certolizumab pegol.
7. A method of claim 1 , wherein the TNF-α antagonist is Golimumab.
8. A method of claim 1 , wherein the TNF-α antagonist is Etanercept.
9. A method of claim 1 further comprising administering an extracellular matrix degradation, depletion or cleavage agent.
10. A method of claim 9 , wherein the extracellular matrix degradation, depletion or cleavage agent is a matrix metalloproteinase and/or a collagenase.
11. A method of claim 9 , wherein the extracellular matrix degradation, depletion or cleavage agent is administered locally to the disease site.